Pretreatment with the dopamine agonist quinpirole inhibits central antihypertensive mechanisms in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 9-10, 1997, Pages 661-666

  Van Den Buuse, M ^a   Tritton, S B ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Blood pressure; Brain; Dopamdine; Quinpirole; Rilmenidine; Sympathetic

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; QUINPIROLE; RILMENIDINE;

ADRENERGIC SYSTEM; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; HEART RATE; HYPERTENSION; INTRACEREBRAL DRUG ADMINISTRATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRESSOR RESPONSE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0030883844     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb02109.x     Document Type: Article

References (20)

1. Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL, Kebabian JW. Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 1981; 292: 463-5.
2. Titus RD, Kornfeld EC, Jones ND et al. Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline. J. Med. Chem. 1983; 26: 1112-16.
3. 3H]quinpirole. Eur. J. Pharmacol. 1991; 203: 105-9.
4. 2 receptor agonist, in the conscious rat. J. Pharmacol. Exp. Ther. 1986; 236: 735-42.
5. Van den Buuse M. Central effects of quinpirole on blood pressure of spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 1992; 262: 303-11.
6. Van den Buuse M, Morton SJ, Cornish JL, Head GA. Prolonged effects of quinpirole on cardiovascular regulation. J. Pharmacol. Exp. Ther. 1996; 277: 473-83.
7. Van den Buuse M. Effects of 7-hydroxy-N,N-di-n-propylaminotetralin on behaviour and blood pressure of spontaneously hypertensive rats. Eur. J. Pharmacol. 1993; 243: 169-77.
8. Van den Buuse M. Differential effects of quinelorane and pergolide on behaviour, blood pressure, and body temperature of spontaneously hypertensive rats and Wistar-Kyoto rats. Pharmacol. Biochem. Behav. 1995; 50: 389-97.
9. 2 receptors in the posterior region of the nucleus tractus solitarius mediate the central pressor action of quinpirole (LY 171555). Brain Res. Bull. 1990; 24: 97-103.
10. 2 receptor agonist: Studies in conscious Brattleboro and Long-Evans rats. J. Pharmacol. Exp. Ther. 1987; 242: 143-51.
11. Van den Buuse M. Pretreatment with quinpirole inhibits the central antihypertensive effects of rilmenidine and α-methyldopa in conscious rats. Eur. J. Pharmacol. 1997; 322: 191-9.
12. Laduron PM, Leysen JM. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem. Pharmacol. 1979; 28: 2161-5.
13. Head GA. Central monoamine systems and new antihypertensive agents. Clin. Exp. Hypertens. 1995; 17: 141-52.
14. Reis DJ. Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. J. Cardiovasc. Pharmacol. 1996; 27: S11-18.
15. 3H]quinpirole binding sites in the rat brain. Synapse 1993; 14: 113-20.
16. 2 receptors on rat vagal afferent neurones. Br. J. Pharmacol. 1995; 114: 1329-34.
17. 2-Agonist activity of the dopamine DA2-agonist LY 171555. J. Cardiovasc. Pharmacol. 1984; 6: 1245-8.
18. Ruffolo RR, Shaar CJ. Relative potency of LY 141865 at dopamine DA2 and histamine H2 receptors. Eur. J. Pharmacol. 1983; 92: 295-6.
19. Badoer E, Head GA, Korner PI. Effects of intracisternal and intravenous α-methyldopa and clonidine on hemodynamics and baroreceptor-heart rate reflex properties in conscious rabbits. J. Cardiovasc. Pharmacol. 1983; 5: 760-7.
20. Chan CKS, Head GA. Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. J. Hypertens. 1996; 14: 855-64.